Insider Selling: MedEquities Realty Trust Inc (MRT) Director Sells 12,816 Shares of Stock

MedEquities Realty Trust Inc (NYSE:MRT) Director Bluemountain Capital Managemen sold 12,816 shares of the firm’s stock in a transaction that occurred on Wednesday, October 10th. The shares were sold at an average price of $9.16, for a total value of $117,394.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Bluemountain Capital Managemen also recently made the following trade(s):

  • On Friday, October 5th, Bluemountain Capital Managemen sold 3,955 shares of MedEquities Realty Trust stock. The shares were sold at an average price of $9.13, for a total value of $36,109.15.
  • On Monday, October 8th, Bluemountain Capital Managemen sold 18,052 shares of MedEquities Realty Trust stock. The shares were sold at an average price of $9.20, for a total value of $166,078.40.

NYSE MRT traded down $0.04 during trading on Friday, hitting $8.79. The company’s stock had a trading volume of 151,484 shares, compared to its average volume of 153,182. The company has a market cap of $309.70 million, a P/E ratio of 7.71 and a beta of -0.07. MedEquities Realty Trust Inc has a 52 week low of $8.64 and a 52 week high of $12.04.

MedEquities Realty Trust (NYSE:MRT) last issued its quarterly earnings results on Wednesday, August 8th. The financial services provider reported $0.10 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.30 by ($0.20). The business had revenue of $17.56 million during the quarter, compared to the consensus estimate of $17.03 million. MedEquities Realty Trust had a return on equity of 5.73% and a net margin of 30.84%. Sell-side analysts expect that MedEquities Realty Trust Inc will post 1.08 earnings per share for the current year.

A number of brokerages recently weighed in on MRT. ValuEngine raised MedEquities Realty Trust from a “sell” rating to a “hold” rating in a research note on Tuesday, July 10th. Zacks Investment Research raised MedEquities Realty Trust from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a research note on Wednesday, July 25th. KeyCorp downgraded MedEquities Realty Trust from an “overweight” rating to a “hold” rating and set a $12.00 price objective on the stock. in a research note on Wednesday, August 8th. Canaccord Genuity cut their price objective on MedEquities Realty Trust from $13.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, August 9th. Finally, B. Riley set a $12.00 price objective on MedEquities Realty Trust and gave the company a “buy” rating in a research note on Thursday, August 9th. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $11.56.

Hedge funds and other institutional investors have recently modified their holdings of the business. Los Angeles Capital Management & Equity Research Inc. bought a new position in MedEquities Realty Trust in the 2nd quarter worth approximately $131,000. People s United Financial Inc. bought a new position in MedEquities Realty Trust in the 2nd quarter worth approximately $158,000. Bank of Montreal Can bought a new position in MedEquities Realty Trust in the 2nd quarter worth approximately $160,000. California Public Employees Retirement System bought a new position in MedEquities Realty Trust in the 2nd quarter worth approximately $171,000. Finally, Barclays PLC increased its position in MedEquities Realty Trust by 252.2% in the 1st quarter. Barclays PLC now owns 16,016 shares of the financial services provider’s stock worth $168,000 after buying an additional 11,469 shares during the period. 90.80% of the stock is currently owned by institutional investors.

MedEquities Realty Trust Company Profile

MedEquities Realty Trust (NYSE: MRT) is a self-managed and self-administered real estate investment trust that invests in a diversified mix of healthcare properties and healthcare-related real estate debt investments. The Company's management team has extensive industry experience in acquiring, owning, developing, financing, operating, leasing and monetizing many types of healthcare properties and portfolios.

See Also: What are the Benefits of Index Funds?

Insider Buying and Selling by Quarter for MedEquities Realty Trust (NYSE:MRT)

Receive News & Ratings for MedEquities Realty Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedEquities Realty Trust and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply